Theoretical and Natural Science
- The Open Access Proceedings Series for Conferences
Proceedings of the International Conference on Modern Medicine and Global Health (ICMMGH 2023)
Series Vol. 6 , 03 August 2023
Open
Access | Article
Analysis of the possibility of effectiveness that therapeutic techniques for diabetes in the treatment of heart failure
* Author to whom correspondence should be addressed.
Abstract
Many studies have revealed that the recurrence of heart failure (HF) in patients with diabetes is significantly higher than that in patients without diabetes, and insulin resistance and abnormal glucose metabolism are common in patients with HF. Therefore, heart failure is an important clinical problem in diabetic patients. Diabetes and heart failure are "killers" that go hand in hand. They share common risk factors. Patients with heart failure frequently have hyperglycemia, and heart failure is a typical complication for diabetic patients. Based on the possible association between the two diseases, this paper will further analyze the therapies of type 2 diabetes (T2DM) and explore whether it can have an effect on how to address heart failure. The study's findings demonstrated that treating type 2 diabetes did have some influence on the management of heart failure and that treating type 2 diabetes did reduce the progression of heart failure symptoms.
Keywords
diabetes mellitus, diabetic cardiomyopathy, heart failure, type 2 diabetes mellitus
References
1. Heart Failure(Congestive Heart Failure), 100 Years of Cleveland Clinic, 800.223.2273
2. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. (2016). "2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC". Eur Heart J. 37 (27): 2129–2200. doi:10.1093/eurheartj/ehw128. PMID 27206819
3. MarwickTH, RitchieR, ShawJE, et al. Implications of underlying mechanisms for the recognition and management of diabetic cardiomyopathy [J]. J Am Coll Cardiol, 2018, 71 (3): 339-351. DOI:10.1016/j.jacc.2017.11.0019
4. BuggerH, AbelED. Molecular mechanisms of diabetic cardiomyopathy [J]. Diabetologia, 2014, 57 (4): 660-671. DOI: 10.1007/s00125-014-3171-6.
5. BurchfieldJS, XieM, HillJA. Pathological ventricular remodeling: mechanisms: part 1 of 2 [J]. Circulation, 2013, 128 (4): 388-400. DOI: 10.1161/CIRCULATIONAHA.113.001878.
6. BerteroE, MaackC. Metabolic remodelling in heart failure [J]. Nat Rev Cardiol, 2018, 15 (8): 457-470. DOI: 10.1038/s41569-018-0044-6.
7. MAYO CLINIC.2020.1. https://mandarin.mayoclinic.org/press-room/diabetes-independently-heart-failure-2020-01-08/
8. Mayo Clinic Proceedings，Population study: Diabetes is an independent predictor of heart failure development
9. Birkeland KI, Bodegard J, Eriksson JW, Norhammar A, Haller H, Linssen GCM, et al. Heart failure and chronic kidney disease manifestation and mortality risk associations in type 2 diabetes: a large multinational cohort study. Diabetes Obes Metab. 2020;22(9):1607–18.
10. Cai X, Liu X, Sun L, He Y, Zheng S, Zhang Y, et al. Prediabetes and the risk of heart failure: A meta-analysis. Diabetes Obes Metab. 2021;23(8):1746–53.
11. Damman K, Hillege HL, van Veldhuisen DJ. Albuminuria in heart failure: a CHARMing new risk factor? Lancet. 2009;374(9689):506–8.
12. van de Wal RM, Asselbergs FW, Plokker HW, Smilde TD, Lok D, van Veldhuisen DJ, et al. High prevalence of microalbuminuria in chronic heart failure patients. J Card Fail. 2005;11(8):602–6.
13. Stehouwer CD, Smulders YM. Microalbuminuria and risk for cardiovascular disease: analysis of potential mechanisms. J Am Soc Nephrol. 2006;17(8):2106–11.
14. Mullens W, Damman K, Testani JM, Martens P, Mueller C, Lassus J, et al. Evaluation of kidney function throughout the heart failure trajectory – a position statement from the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2020;22(4):584–603.
15. Sacre JW, Magliano DJ, Shaw JE. Heart failure hospitalisation relative to major atherosclerotic events in type 2 diabetes with versus without chronic kidney disease: a meta-analysis of cardiovascular outcomes trials. Diabetes Metab. 2021;47(5):101249.
16. Lawson CA, Seidu S, Zaccardi F, McCann G, Kadam UT, Davies MJ, et al. Outcome trends in people with heart failure, type 2 diabetes mellitus and chronic kidney disease in the UK over twenty years. EClin Med. 2021;32:9.
17. Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol JASN. 2009;20(8):1813–21.
18. Guariguata, L, Whiting, DR, Hambleton, I, Beagley, J, Linnenkamp, U, Shaw, JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103:137–149. doi: 10.1016/j.diabres.2013.11.002 Crossref. PubMed.
19. Zimmet, P, Alberti, KG, Magliano, DJ, Bennett, PH. Diabetes mellitus statistics on prevalence and mortality: facts and fallacies. Nat Rev Endocrinol. 2016;12:616–622. doi: 10.1038/nrendo.2016.105 Crossref. PubMed.
20. Diabetes - WHO | World Health Organization
21. R Paul Robertson, MDMiriam S Udler, MD, PhD. Pathogenesis of type 2 diabetes mellitus. Dec 14, 2021. https://www.uptodate.com/contents/pathogenesis-of-type-2-diabetes-mellitus#H40
22. Harris MI. Impaired glucose tolerance in the U.S. population. Diabetes Care 1989; 12:464.
23. Mokdad AH, Ford ES, Bowman BA, Nelson DE, Engelgau MM, Vinicor F, Marks JS. Diabetes trends in the United States, 1990-1998. Diabetes Care. 2000;23:1278–1283. [PubMed]
24. Reaven GM, Hollenbeck C, Jeng C-Y, Wu MS, Chen Y-DI. Measurement of plasma glucose, free fatty acid, lactate, and insulin for 24 hours in patients with NIDDM. Diabetes. 1988;37:1020–1024. [PubMed]
25. DeFronzo, R. A. Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes 58, 773–795 (2009). A classic review of the aetiology of T2DM, with a therapeutic approach based on its pathophysiology.
26. Jansson P-A, Larsson A, Smith U, Lonroth P. Lactate release from the subcutaneous tissue in lean and obese men. J Clin Invest. 1994;93:240–246. [PMC free article] [PubMed]
27. Bugger H, Abel ED. Molecular mechanisms of diabetic cardiomyopathy. Diabetologia. 2014;57:660–671. Crossref. PubMed.
28. Helena C. Kenny and E. Dale Abel. Heart Failure in Type 2 DiabetesMellitus. Impact of Glucose-Lowering Agents, Heart Failure Therapies, and Novel Therapeutic Strategies. 2019;124:121–141
29. Correction to: Effect of Empagliflozin on the Clinical Stability of Patients With Heart Failure and a Reduced Ejection Fraction: The EMPEROR-Reduced Trial. Circulation. 2021-01-26, 143 (4). ISSN 0009-7322. doi:10.1161/cir.0000000000000954.
30. DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol 2017; 13: 11-26.
31. Hao Lizhi, Zhang Yayi, Yang Chunyi et al. American Diabetes Association 2018 Standard Management Recommendations for diabetic nephropathy. Chinese Journal of Internal Medicine 2018; 29:250-61.
32. WilcoxCS. Antihypertensive and renal mechanisms of SGLT2 (sodium-glucose linked transporter 2) inhibitors [J]. Hypertension, 2020, 75 (4): 894-901. DOI: 10.1161/HYPERTENSIONAHA.119.11684.
33. NewmanJC, VerdinE. β-hydroxybutyrate: much more than a metabolite [J]. Diabetes Res Clin Pract, 2014, 106 (2): 173-181. DOI: 10.1016/j.diabres.2014.08.009.
34. MartensP, MathieuC, VerbruggeFH. Promise of SGLT2 inhibitors in heart failure: diabetes and beyond [J]. Curr Treat Options Cardiovasc Med, 2017, 19 (3): 23. DOI: 10.1007/s11936-017-0522-x.
Data Availability
The datasets used and/or analyzed during the current study will be available from the authors upon reasonable request.
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License. Authors who publish this series agree to the following terms:
1. Authors retain copyright and grant the series right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this series.
2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the series's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this series.
3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See Open Access Instruction).
- Volume Title
- Proceedings of the International Conference on Modern Medicine and Global Health (ICMMGH 2023)
- ISBN (Print)
- 978-1-915371-65-2
- ISBN (Online)
- 978-1-915371-66-9
- Published Date
- 03 August 2023
- Series
- Theoretical and Natural Science
- ISSN (Print)
- 2753-8818
- ISSN (Online)
- 2753-8826
- DOI
- 10.54254/2753-8818/6/20230221
- Copyright
- © 2023 The Author(s)
- Open Access
- This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited